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ABSTRACT
Objective: The objective of the study was to evaluate the disease Amavata with current understanding of International Classification of Diseases (ICD) 
2010.
Methods: For the present clinical study, a total of 100 patients were selected. Selection of the patients was done using subjective criteria (mentioned 
in Ayurvedic samhitas) to diagnose Amavata. Moreover, these patients were classified into three stages according to duration (<6 months, more than 
6 months, more than 1 year) of disease. Laboratory investigations were advised such as hematological parameters and collagen profile.
Results: A total of 100 cases of Amavata were divided into two groups based on ICD classification 2010. 86 cases of Amavata patients were diagnosed 
as rheumatoid arthritis including all the three stages. 14 cases of Amavata were diagnosed as systemic lupus erythematosus, reactive arthritis, and 
ankylosing spondylitis including all the three stages.
Conclusion: Amavata is a syndrome may be correlated to arthropathies described under ICD classification 2010.
Keywords: Amavata, Rheumatoid arthritis, Systemic lupus erythematosus, Reactive arthritis, Ankylosing spondylitis.
INTRODUCTION
Due to consumption of Vata, Pitta, and Kapha aggravating factors [1] 
and substances which favors the formation of Ama causes sluggish 
functions of Agni and develops Ama inside the gastrointestinal tract 
[2] and enters the Trika region (joints where more than two bones 
unite to form an anatomical structure called Trika Sandhi) and Sandhi 
pradesha (various joints of body) causing Stabdhata (stiffness) in joints 
leading to genesis of Amavata [3]. Amavata is considered as rheumatoid 
arthritis (RA) only since a long period but other diseases mentioned 
under arthropathies also fulfills the diagnostic criteria of Amavata. 
The aim of this study is to evaluate the disease Amavata with current 
understanding of International Classification of Diseases 2010.
METHODS
Study design
Selection of the patients was done using subjective criteria mentioned 
for the clinical diagnosis of Amavata, and all the selected patients were 
advised to undergo ancillary investigation to diagnose the diseases 
from current perspectives.






a. Registered patients belonged to age group >15 years
b.	 Patients	who	fulfilled	the	criteria	of	diagnostic	features	of	Amavata 
(Samanya Lakshana and Pravriddha Lakshana).
Exclusion criteria
a. Patients with age below 15 years
b.	 Patients,	who	did	not	fulfill	Amavata diagnostic criteria.
Selection of the patients was done from September 2012 to March 2013 
from the Vikriti Vigyan and Rheumatology OPDs.
Ethical committee
Ethical clearance was taken from the institutional ethics committee.
Diagnostic criteria of Samanya Lakshana of Amavata [4]
Daurbalya (weakness), Gauravam hridayasya (heaviness in precordial 
region), Trika Sandhi Praveshakau Stabdham (stiffness in joints), 
Angamarda (bodyache), Aruchi (anorexia), Trishna (thirst), Alasya 
(lethargy), Gauravam (heaviness), Jvara (fever), Apaka (indigestion), 
and Shunata Anganam (swelling).
Specific or Pravriddha Lakshana of Amavata [3]
Hasta Padashiro Gulpha Trika Janu Uru Sandhi Sa Rujam Shotham 
(pain and swelling in hand, feet, ankle, knee, hip, and spinal joints), 
Rujyate Atyartham (excruciating pain), Vyaviddha Iva Vrishcika (pain 
like scorpion sting), Agnidaurbalya (hindered digestive mechanism), 
Praseka (excessive salivation), Aruchi (anorexia), Gauravam 
(heaviness), Utsahahani (lack of enthusiasm), Vairasya (altered 
taste of mouth cavity), Daham (burning sensation), Bahumutratam 
(excessive urination), Kukshau Kathinatam Shulam (hardness and pain 
in abdomen), Nidraviparyaya (disturbed sleep), Trit (thirst), Chardi 
(nausea), Bhrama (fainting), Murccha (unconsciousness), Hrid Graha 
(stiffness in pericordium), Vidvibaddhatam (constipation), Jadya 
(stiffness), Antrakujanam (intestinal gurgling), and Anaha (distension 
in abdomen).
Investigation profile
•	 Hematological	parameters	 -	Complete	blood	 count,	 erythrocyte	
sedimentation rate.
•	 Collagen	profile	 including	C-reactive	protein,	 rheumatoid	 factor,	
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Statistical analysis
Chi-squared	 test	 and	 Z	 test	 were	 used	 to	 compare	 the	 incidence	 of	
symptoms between two groups.
Indication of significant or non-significant
When the result is significant, it means there is significant difference 
between groups for an individual symptom. That symptom may have 
high	frequency	in	any	group.	If	the	result	is	non-significant	it	means	the	
possibility of a particular symptom for its presence or absence is same 
in all groups.
OBSERVATION AND RESULTS
Stage	1:	Total	15	cases	of	Amavata patients were belonged to <6 months 
duration.
Stage	2:	Total	10	cases	of	Amavata patients were belonged to more than 
6 months duration.
Stage	3:	Total	75	cases	of	Amavata patients were belonged to more than 
1 year duration.
A total of 100 cases of Amavata were subjected to complete blood 
count, erythrocyte sedimentation rate, and collagen profile. On 
the basis of investigation report Amavata patients divided into two 
groups.
Group	 A	 (n=86):	 RA.	 13	 cases	 of	 Stage	 1,	 9	 of	 Stage	 2	 and	 64	 of	
Stage 3.
Group	 B	 (n=14):	 Comprises	 systemic	 lupus	 erythematosus	 (SLE),	
reactive arthritis (Re.A), and ankylosing spondylitis (AS), and these 
were further subdivided into subgroups.





Due to less number of cases in all three subgroups of Group 2, statistical 
analysis was analyzed as Group 2 in different stages.
36% cases of Amavata	were	observed	in	the	age	group	of	25-34	years	
(Table 1).
84% patients of RA were females. 100% patients of SLE were females 
(Table 2).
Assessment of Samanya Lakshana of Amavata
I. In Stage 1 (n=15)
•	 Group	A	 (n=13)	 -	Trika Sandhi Pravehakau Stabdham, Jvara, 
Apaka and Shunata Anganama were present in all cases (100%) 
followed by Daurbalya and Alasya	(92%).
•	 Group	B	(n=2):
  Subgroup 1 (n=0) has no case.
   Subgroup 2 (n=1) Patient has all symptoms except Trishna 
and Aruchi.
   Subgroup 3 (n=1) Patient has all symptoms except Gauravam 
Hrdayasya, Trishna and Jvara.
II. In Stage 2 (n=10)
•	 Group	A	(n=9)	–	maximum	symptoms were present in all cases, 
i.e., 100%).
•	 Group	B	(n=1):
	 	 	Subgroup	1	(n=1):	Patient	has	all	symptoms	except	Trishna 
and Jvara.
	 	 Subgroup	2	and	Subgroup	3	(n=0):	No	cases.
III. In Stage 3, n=75 showing in Table 3.
Group A (n=64)
Angamarda was present in all cases, i.e., 100%, followed by followed by 
Daurbalya, Trika sandhi praveshakau stabdham and Shunata anganama 
(97%),	 Apaka	 (94%),	 Alasya	 (92%),	 Aruchi (73%), Jvara (64%), 
Gauravam (63%), Trishna (41%), and Gauravam hridayasya (25%).
Table 2: Sex wise distribution in the two groups of Amavata (n=100)








Male 14 (16) 0 (0) 2 (40) 2 (66) 18 (18)
Female 72 (84) 6 (100) 3 (60) 1 (33) 82 (82)
SLE:	Systemic	lupus	erythematosus,	Re.A:	Reactive	arthritis,	AS:	Ankylosing	spondylitis,	RA:	Rheumatoid	arthritis
Table 3: Assessment of Samanya Lakshana of Amavata in Stage 3 (n=75) and comparison of symptoms between two groups
S. No. Symptoms Group A (n=64) Group B (n=11) Z value and p value






1 Daurbalya 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
2 Gauravam Hrdayasya 16 (25) 3 (60) 1 (25) 2 (100) Z=1.88,	p>0.05
3 Trika Sandhi Praveshakau Stabdham 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
4 Angamarda 64 (100) 5 (100) 4 (100) 2 (100) Z=0,	p>0.05
5 Aruchi 47 (73) 5 (100) 4 (100) 2 (100) Z=4.86,	p<0.01
6 Trishna 26 (41) 4 (80) 3 (75) 1 (50) Z=2.17,	p<0.05
7 Alasya 59	(92) 5 (100) 4 (100) 2 (100) Z=2.35,	p<0.05
8 Gauravam 40 (63) 5 (100) 4 (100) 1 (50) Z=2.6,	p<0.01
9 Jvara 41 (64) 5 (100) 4 (100) 2 (100) Z=6,	p<0.01
10 Apaka 60	(94) 5 (100) 4 (100) 2 (100) Z=2.02,	p<0.05
11 Shunata Anganama 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
SLE:	Systemic	lupus	erythematosus,	Re.A:	Reactive	arthritis,	AS:	Ankylosing	spondylitis,	RA:	Rheumatoid	arthritis
Table 1: Age wise distribution of the Amavata patients (n=100)
S. No. Age group (years) Total (%)
1 15-24 4 (4)
2 25-34 36 (36)
3 35-44 28 (28)
4 45-54 24 (24)
5 55-64 8 (8)
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Group B (n=11)
Subgroup 1 (n=5)
Most of symptoms were present in all cases, i.e., 100%.
Subgroup 2 (n=4)
Most of symptoms were present in all cases, i.e., 100%.
Subgroup 3 (n=2)
Most of symptoms were present in all cases, i.e., 100%.
Comparison between Group 1 and Group 2
Due	to	very	less	registered	cases	in	Stage	1	and	2,	“Z”	test	could	not	be	
applied due to which comparison could not be done.
But	 in	 Stage	 3,	 “Z”	 is	 applied	 and	 on	 comparison	 –	 Table 3 shows 
that between the all symptoms of Amavata as Alasya, Aruchi, Trishna, 
Gauravam, Jvara, and Apaka show significant result.
Assessment of Pravriddha Amavata Lakshana of Amavata
I. In Stage 1 (n=15)
•	 Group	 A	 (n=13):	Hasta Padashiro Gulpha Trika Janu Uru 
Sandhishau Sarujam Shotham, Rujyate Atyartham, Vyaviddha 
Iva Vrishcika, Agnidaurbalya, Daham and Jadya were present in 





II. In Stage 2 (n=10)
•	 Group	 A	 (n=9):	 Agnidaurbalya, Gauravam, Utsahahani, 
Bahumutratam, and Hrid Graha were present in all cases, 
i.e., 100%, followed by Hasta Padashiro Gulpha Trika Janu Uru 





III. In Stage 3 (n=75) showing in Table 4.
Group 1 (n=64)
Hasta Padashiro Gulpha Trika Janu Uru Sandhishau Sarujam Shotham, 
Rujyate Atyartham, Utsahahani and Jadya were	present	 in	97%	cases,	
i.e., followed by Agnidaurbalya	(94%).
Group 2 (n=11)
Subgroup 1 (n=5)
Most of symptoms were present in all cases, i.e., 100%.
Subgroup 2 (n=4)
Most of symptoms were present in all cases, i.e., 100%.
Subgroup 3 (n=2)
Most of symptoms were present in all cases, i.e., 100%.
Comparison between Group 1 and Group 2
In	Stage	3,	“Z”	test	is	applied	and	on	comparison	it	was	observed	that	
between the all symptoms of Pravriddha Amavata Agnidaurbalya, 
Aruchi, Gauravam, Kukshaukathinatama Shulam, and Trit show 
significant result.
Observation on objective criteria
Out of 100 patients of Amavata the erythrocyte sedimentation rate 
was	within	normal	 limit	 in	 11	 cases,	 ESR	was	 increased	 in	 29	 cases,	
i.e. >20mm in 1st hr and high ESR value, i.e., >40 mm in 1st hr was 
observed in 60 cases (Table 5).
RA factor titer was higher in 86 cases and it was within normal limit in 
14 cases (Table 6).
C-reactive	 protein	 value	 was	 higher	 in	 91	 cases	 and	 it	 was	 within	
normal	limit	in	9	cases	(Table 7).
Table	8	shows	that	out	of	35	registered	cases	17%	cases	had	the	anti-
CCP	 value	 within	 normal	 range	 while	 83%	 cases	 had	 the	 anti-CCP	
Table 4: Assessment of Pravriddha Lakshana of Amavata in Stage 3 (n=75) and comparison of symptoms between 2 groups









1 Hasta Padashiro Gulpha Trika 
Janu Uru Sandhishau Sarujam 
Shotham
62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
2 Rujyate Atyartham 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
3 Vyaviddha Iva Vrishcika 57	(89) 5 (100) 4 (100) 0 (0) Z=0.572,	p>0.05
4 Agnidaurbalya 60	(94) 5 (100) 4 (100) 2(100) Z=2.02,	p<0.05
5 Praseka 26 (41) 2 (40) 2 (50) 0 (0) Z=0.317,	p>0.05
6 Aruchi 47 (73) 5 (100) 4 (100) 2 (100) Z=4.86,	p<0.01
7 Gauravam 40 (53) 5 (100) 4 (100) 1 (50) Z=3.56,	p<0.01
8 Utsahahani 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
9 Vairasya 42 (66) 3 (60) 3 (75) 0 (0) Z=0.682,	p>0.05
10 Daham 57	(89) 5 (100) 4 (100) 0 (0) Z=0.572,	p>0.05
11 Bahumutratam 34 (53) 3 (60) 1 (25) 2 (100) Z=0.123,	p>0.05
12 Kukshau Kathinatam Shulam 34 (53) 5 (100) 2 (50) 2 (100) Z=2.02,	p<0.05
13 Nidraviparyaya 47 (73) 5 (100) 3 (75) 1 (50) Z=0.700,	p>0.05
14 Trit 26 (35) 4 (80) 3 (75) 1 (50) Z=2.59,	p<0.01
15 Chardi 38	(59) 5 (100) 2 (50) 2 (100) Z=1.75,	p>0.05
16 Bhrama 53 (83) 5 (100) 3 (75) 2 (100) Z=0.814,	p>0.05
17 Murccha 0 (0) 0 (0) 0 (0) 0 (0) 0
18 Hrid Graha 16 (25) 3 (60) 1 (25) 2 (100) Z=1.88,	p>0.05
19 Vidvibaddhatam 53 (83) 3 (60) 3 (75) 1 (50) Z=1.24,	p>0.05
20 Jadya 62	(97) 5 (100) 4 (100) 2 (100) Z=1.40,	p>0.05
21 Antrakujanam 53 (83) 4 (80) 2 (50) 1 (50) Z=1.24,	p>0.05
22 Anaha 44	(69) 3 (60) 4 (100) 2 (100) Z=1.004,	p>0.05
SLE:	Systemic	lupus	erythematosus,	Re.A:	Reactive	arthritis,	AS:	Ankylosing	spondylitis,	RA:	Rheumatoid	arthritis
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Amavata results from the complex interactions between Vata, Kapha, 
Ama, environmental factors, and the immune system. Improper diet and 
lifestyle disturbs the leads to abnormal homeostasis of Doshas resulting 
into sluggish functions of Agni leading to development of Ama .
Ama combines with agitated Vata moves to Kaphasthanas and develops 
the disease Amavata.
A total of 100 registered cases who fulfilled the diagnostic criteria of 




of Amavata were further divided into following groups based on the 
objective criteria that fulfilled the diagnosis of respective diseases, 
i.e., Group 1, 86 patients of Amavata were diagnosed as RA, 6 patients 
were diagnosed as SLE; 5 patients were diagnosed as Re.A and 
3 patients were diagnosed as AS. It may be concluded that Amavata 
is a syndrome and may be correlated to arthropathies mentioned 
in modern medicine. Table	 1	 shows	 that	 36%	 patients	 were	 of	 25-
34	years	age	group	followed	by	28%	patients	were	of	35-44	years	age	
group. It has mentioned that onset of the majority of the arthropathy 
were	 frequently	 diagnosed	 during	 the	 2nd and 4th decades of life [5]. 
86% patients of Amavata were diagnosed as RA and out of these 84 % 
patients were female which was almost similar to studies conducted 
by	 Al-	 Bishri	 et al. (78% vs. 22%, respectively) and Bajraktari et al. 
(76.8% vs. 23.2%, respectively) [6].It may be due to hormonal factor 
and sex linked genes. Table 2 shows that 100% cases of diagnosed SLE 
were female. SLE is a chronic inflammatory disease that has a protean 
manifestation.	 More	 than	 90%	 of	 cases	 are	 seen	 in	 women.	 SLE,	 an	
autoimmune disorder characterized by multisystem inflammation 
with the generation of autoantibodies [7].This study provides the base 
for research to innovate and select the drugs mentioned for Amavata 
management may be screened to invent the drugs for the better 
management of challenging arthropthies.
About 86% patients were of RA which has very similar pathogenesis of 
Amavata which is stated by Turnbagh theory. Turnbagh and coworkers 
suggested that a set of core microbiome is present in humans living in 
a certain habitat conditions. Variability among individuals could arise 
due to the host lifestyle, diet, health, immune system, and environment. 
In this theory, they described that RA is a multifactorial disease and 
requires	 interaction	 between	 genetic	 and	 environmental	 factors	 for	
predisposition. The presence of bacterial DNA of the gut residing 
commensals in synovium as well as dysbiosis of certain commensal 
bacteria in fecal samples of RA patients as compared to controls suggest 
a significant role of the gut flora in pathogenesis of RA [8]. This concept 
described in Ayurveda as erratic diet and lifestyle causes variability in 
gut due to hindered digestive power as a result disturbed Agni yields 
immature Rasa (Ama) in Amashaya . It is absorbed in the system and 
taken up by aggravated and vitiated Vata especially to the Kapha 
sthana mainly Amashaya, Sandhi, Uras, Kantha, etc., and causes genesis 
of symptom complex. This concept of Amavata pathogenesis may be 
proved scientifically by this theory.
Table 5: The ESR in diagnosed Amavata patients (n=100)
S. No. ESR range in mm/1st hr <20 >20 >40
1 Total number of cases 11 29 60
ESR:	Erythrocyte	sedimentation	rate
Table 6: The RA factor titer in diagnosed Amavata 
patients (n=100)
S. No. RA factor titer Evaluation Total number of 
individual (%)
1 >20	IU/ml Positive 86 (86)
2 <20	IU/ml Negative 14 (14)
RA:	Rheumatoid	arthritis
Table 7: The C-reactive protein value in diagnosed Amavata 
patients (n=100)
S. No. C-reactive protein value Evaluation Total number 
of individual
n=100 (%)
1 >0.6	mg/dl Positive 91	(91)
2 <0.6	mg/dl Negative 9	(9)
Table 8: The anti CCP value in misdiagnosed patients Amavata 
as rheumatoid arthritis (n=35)
S. No. Anti CCP Evaluation Total number of individual
n=35 (%)
1 >25	U/ml Positive 29	(83)
2 <25U/ml Negative 6 (17)
CCP:	Cyclic	citrullinated	peptide
Table 9: The antinuclear antibody assay in diagnosed Amavata 
patients (n=14) having negative result for RA factor
S. No. Antinuclear antibody Evaluation Total 
number (n=14)
1 >1.4 Positive 10
2 <1 Negative 4
3 1-1.4 Equivocal 0
RA:	Rheumatoid	arthritis
Table 10: The anti dsDNA antibody test in diagnosed Amavata 
patients (n=10) having ANA test positive
S. No. Anti dsDNA (IU/ml) Evaluation Total number of 
individual (%)
1 >55 Positive 6 (60)
2 <35 Negative 4 (40)
3 35-55 Equivocal 0 (0)
ANA:	Antinuclear	antibody,	dsDNA:	Double	stranded	DNA
Table 11: The HLA B27 genotyping result in diagnosed Amavata 
patients (n=8) with 4 cases with ANA negative and 4 cases with 
anti dsDNA negative but ANA positive result
S. No. HLA B27 Total number of individual (%)
1 Positive 5 (62)
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CONCLUSION
It may be concluded that Amavata may be correlated to RA, SLE, Re.A, 
and AS. This clinical study provides vital clue for the management 
of above arthritis from Ayurveda perspectives based on Amavata 
management principles. Further, it also helps to invent the newer 
therapeutic combination from the Amavata treatment principles to 
manage these challenging arthropathies.
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